Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism.

United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism.

Journal: Expert opinion on drug safety
Published: August 18, 2023

Pre- and Postlicensure Animal Efficacy Studies Comparing Anthrax Antitoxins.

Pre- and Postlicensure Animal Efficacy Studies Comparing Anthrax Antitoxins.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 17, 2022

Survival of Patient With Hemorrhagic Meningitis Associated With Inhalation Anthrax.

Survival of Patient With Hemorrhagic Meningitis Associated With Inhalation Anthrax.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: May 06, 2022

Exotoxin-Targeted Drug Modalities as Antibiotic Alternatives.

Exotoxin-Targeted Drug Modalities as Antibiotic Alternatives.

Journal: ACS infectious diseases
Published: January 31, 2022

A Novel Toll-Like Receptor 2 Agonist Protects Mice in a Prophylactic Treatment Model Against Challenge With Bacillus anthracis.

A Novel Toll-Like Receptor 2 Agonist Protects Mice in a Prophylactic Treatment Model Against Challenge With Bacillus anthracis.

Journal: Frontiers in microbiology
Published: October 27, 2021

Monoclonal Antibodies for Protozoan Infections: A Future Reality or a Utopic Idea?

Monoclonal Antibodies for Protozoan Infections: A Future Reality or a Utopic Idea?

Journal: Frontiers in medicine
Published: July 22, 2021

A Review of the Efficacy of FDA-Approved B. anthracis Anti-Toxin Agents When Combined with Antibiotic or Hemodynamic Support in Infection- or Toxin-Challenged Preclinical Models.

A Review of the Efficacy of FDA-Approved B. anthracis Anti-Toxin Agents When Combined with Antibiotic or Hemodynamic Support in Infection- or Toxin-Challenged Preclinical Models.

Journal: Toxins
Published: December 15, 2020

Extrapolation and dosing recommendations for raxibacumab in children from birth to age <18 years.

Extrapolation and dosing recommendations for raxibacumab in children from birth to age <18 years.

Journal: British journal of clinical pharmacology
Published: December 11, 2020

Population pharmacokinetics of raxibacumab in healthy adult subjects.

Population pharmacokinetics of raxibacumab in healthy adult subjects.

Journal: British journal of clinical pharmacology
Published: December 11, 2020

Raxibacumab: a panacea for anthrax disease?

Raxibacumab: a panacea for anthrax disease?

Journal: The Lancet. Infectious diseases
Published: February 28, 2020

Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study.

Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study.

Journal: The Lancet. Infectious diseases
Published: November 15, 2019

Monoclonal Antibodies Against Infectious Microbes: So Long and Too Little!

Monoclonal Antibodies Against Infectious Microbes: So Long and Too Little!

Journal: Infectious disorders drug targets
Published: August 21, 2019
Showing 1-12 of 33

Last Updated: 10/31/2025